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Pegzilarginase in combination with agonist anti-OX40 therapy enhances effector 
function leading to improved tumor regression and survival
METHODS
CONCLUSIONS & FUTURE DIRECTIONS
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Day 8 Day 12
+aOX40 (250 ug)
monitor for
survival 
Figure 2. CT26 tumor cells were inoculated on d0. Eight days later, mice were treated 
with pegzilarginase+/-aOX40 (ip). Three days later, TIL and LN were harvested for flow 
analysis. **P<0.01.
-Combination therapy associated with increased T-cell activation (IFN-g, gzmA) 
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Figure 1. CT26 or MCA-205 tumors were implanted on day 0. On day 8, animals were 
treated with pegzilarginase+/-aOX40 (ip). Pegzilarginase was administered 1x/week 
for 4 weeks. Tumors were measured 2x/wk or until tumor burden was >175 mm^2. 
rat IgG rat IgGpegzilarginase pegzilarginase
aOX40aOX40 pegzilarginase/ aOX40
1e6 CT26 (BALB/c) or 7.5e5 MCA-205 (C57BL/6) cells were implanted on day 0. For 
survival studies, mice were dosed with pegzilarginase+/-aOX40 on day 8, with a 
second dose of aOX40 on day 12. Subsequent doses of pegzilarginase were given 
weekly for 4 weeks. Graphs represent combined data from two replicate experiments. 
For flow analysis experiments, treatment also began on day 8, followed by tissue har-
vest 1 week later. Statistics were analyzed by one-way ANOVA. *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001.
Figure 3. Myeloid compartment of CT26 TIL was analyzed for frequency of total 
macrophages, monocytes and neutrophils on d3 and d7 post-treatment. Arg1: argin-
ase; MFI: Mean fluorescence intensity
-Combination therapy led to decreased arginase in myeloid cells
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-Arginine depletion through pegzilarginase synergizes with 
aOX40 to impair tumor progression.
-Combined pegzilarginase/aOX40 demonstrated superior 
anti-tumor activity relative to monotherapy. 
-Enhanced efficacy is associated with increased effector T 
cell function.
-These data support exploration of this novel combination 
in future clinical trials. 
** *
Tumors defective in arginine bio-
synthesis are dependent on 
extracellular arginine.
In syngeneic tumor models, arginine depletion through pegzilarginase 
treatment has been shown (poster p#345) to:
Induce tumor autophagy
Increase MHCII expression
Activate T cells
Given that T cell activation can induce OX40 expression, we hypothe-
sized that the combination of pegzilarginase with an OX40 agonist 
(aOX40) could synergize to enhance T cell priming and effector function, 
resulting in improved anti-tumor activity.
Figure 4. Graphs depict cell frequency (top) or mean fluorescence intensity (MFI) (bot-
tom) compared to tumor burden using a Spearman correlation. Correlation plots (top), 
depict results from invidividual mice. Two cell types (Ki-67+CD8+; macrophage iNOS 
MFI) were selected to demonstrate negative correlations with tumor size, indicating 
that greater % or increased MFI of these phenotypes correlates with a smaller tumor 
size. Teff PD-1+ and macrophage CD206 MFI highlight positive correlations with tumor 
size. Spearman correlations and their significance for all cell phenotypes are repre-
sented by a heat map (bottom). *P<0.05, **P<0.01, ***P<0.001. 
Pegzilarginase (AEB1102; Aeglea 
Biotherapeutics) is a bioengineered 
pegylated human arginase 1 currently 
in clinical trials.
1Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR
2Aeglea BioTherapeutics, Inc, Austin, TX
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